Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting

Revista Portuguesa de Cardiologia

Volumn 33, Issue 9, 2014, Pages 535-544

  Morais, João ^a   Aguiar, Carlos ^b   McLeod, Euan ^c   Chatzitheofilou, Ismini ^c   Fonseca Santos, Isabel ^d   Pereira, Sónia ^d  

^a Hospital de Santo Andre   (Portugal)

^b HOSPITAL DE SANTA CRUZ   (Portugal)

^c IQVIA   (United States)

^d SA   (Portugal)

Author keywords

Atrial fibrillation; Cost effectiveness; Portugal; Rivaroxaban; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTUGAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC DISEASE; TREATMENT OUTCOME; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE PLANNING; MARKOV CHAIN; MORTALITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STROKE; TIME FACTOR; UTILIZATION;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEALTH RESOURCES; HUMANS; MARKOV CHAINS; PORTUGAL; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; RIVAROXABAN; SENSITIVITY AND SPECIFICITY; STROKE; TIME FACTORS; WARFARIN;

EID: 84908212644     PISSN: 08702551     EISSN: 21742030     Source Type: Journal    
DOI: 10.1016/j.repc.2014.02.020     Document Type: Article

References (42)

1. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the ACC/AHA Task Force on practice guidelines and the ESC Committee for practice guidelines Eur Heart J 27 2006 1979 2030
2. M.B. Iqbal, A.K. Taneja, and G.Y. Lip Recent developments in atrial fibrillation BMJ 330 2005 238 243
3. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
4. P.A. Wolf, R.D. Abbott, and W.D. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 893 898
5. C. Marini, F. De Santis, and S. Sacco Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
6. D. Bonhorst, M. Mendes, and P. Adragão Prevalência de fibrilhação auricular na população portuguesa com 40 ou mais anos. Estudo FAMA Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: The FAMA study Rev Port Cardiol 29 2010 331 350
7. Coordenação Nacional para as Doenças Cardiovasculares Terapêutica Antitrombótica da Fibrilhação Auricular 2009, March Alto Comissariado da Saúde
8. K.L. Furie, L.B. Goldstein, and G.W. Albers Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation. A science advisory for healthcare professionals from the American Heart Association/American Stroke Association Stroke 43 2012 3442 3453
9. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
10. R. De Caterina, S. Husted, and L. Wallentin New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper J Am Coll Cardiol 59 2012 1413 1425
11. J. Ansell, J. Hirsh, and L. Poller The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 Suppl. 2004 204S 233S
12. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Europace 12 2010 1360 1420
13. Approved Summary of Product Characteristics (Xarelto).
14. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Eng J Med 365 2011 883 891
15. Eurohealth - European Observatory on Health Systems and Policies Quarterly of the European Observatory on Health Systems and Policies Health systems and the financial crisis 18 2012 1
16. J. Kleintjens, X. Li, and S. Simoens Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting Pharmacoeconomics 31 2013 909 918
17. E.A. Silva, C.G. Pinto, and C. Sampaio Orientações metodológicas para estudos de avaliação económica de medicamentos 1998 INFARMED Lisboa
18. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
19. Instituto Nacional de Estatística. Departamento de estatísticas demográficas e sociais. Tábua Completa de Mortalidade 2008-2010.
20. B.D. Hoit, E.A. Gilpin, and H. Henninh Myocardial infarction in young patients: an analysis by age subsets Circulation 74 1986 712 721
21. M.J. Drummond, B. O'Brien, and G.L. Stoddart Methods for the economic evaluation of health care programmes 2nd ed. 1997 Oxford Medical Publications
22. J. Berg, P. Lindgren, and R. Nieuwlaat Factors determining utility measured with the EQ-5D in patients with atrial fibrillation Qual Life Res 19 2010 381 390
23. A. Robinson, R. Thomson, and D. Parkin How patients with atrial fibrillation value different health outcomes: a standard gamble study J Health Serv Res Policy 6 2001 92 98
24. P.W. Sullivan, T.W. Arant, and S.L. Ellis The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US Pharmacoeconomics 24 2006 1021 1033
25. S. Hallan, A. Asberg, and B. Indredavik Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes J Intern Med 246 1999 309 316
26. Ministério da Saúde. Diário da República - I Série, N.° 21. Portaria n.° 139/2009, de 30 de janeiro (corrigida pela Portaria n.° 839-A/2009, de 31 de Julho). 2009.
27. Ministério da Saúde. Diário da República - I Série, N.° 106. Portaria n.° 220/2011, de 11 de Junho. 2011.
28. Administração Central dos Serviços de Saúde. Contabilidade Analítica dos Hospitais do SNS. [Online] 2006. http://www.acss.min-saude.pt/Portals/0/DownloadsPublicacoes/SNS/Infogestao/ContabAnalitica2006HospitaisSNS.pdf
29. INFARMED. INFOMED. [Online] www.infarmed.pt/infomed/inicio.php.
30. A. Macedo, J. Carrasco, and S. Andrade Estudo de avaliação do custo incremental da auto-monitorização do INR versus controlo laboratorial ou monitorização no centro de saúde, em Portugal Acta Med Port 23 2010 203 212
31. H. Heidbuchel, P. Verhamme, and M. Alings European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
32. C. Aguiar Avanços recentes na prevenção do tromboembolismo na fibrilhação auricular Rev Port Cardiol 29 Supl. II 2010 33 45
33. R. Nieuwlaat, A. Capucci, and G.Y. Lip Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation Eur Heart J 27 2006 3018 3026
34. E.M. Hylek, J. D'Antonio, and C. Evans-Molina Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation Stroke 37 2006 1075 1080
35. E. Birman-Deych, M.J. Radford, and D.S. Nilasena Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation Stroke 37 2006 1070 1074
36. A.L. Waldo, R.C. Becker, V.F. Tapson for the NABOR Steering Committee Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation J Am Coll Cardiol 46 2005 1729 1736
37. Oxford Outcomes Network meta-analysis incorporating results of the ROCKET trial (Stroke prevention in atrial fibrillation) 2011
38. J. Protheroe, T. Fahey, and A.A. Montgomery The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis BMJ 320 2000 1380 1384
39. L.S. Miguel, E. Rocha, and J. Ferreira Avaliação económica do dabigatrano na prevenção de acidentes vasculares cerebrais isquémicos em doentes com fibrilação auricular não valvular Rev Port Cardiol 32 2013 557 565
40. B.L. Limone, W.L. Baker, and J. Kluger Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models PLoS ONE 8 2013 e62183
41. I.M. Ogilvie, N. Newton, and S.A. Welner Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645
42. R. Nieuwlaat, A. Capucci, and A.J. Camm Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434